trending Market Intelligence /marketintelligence/en/news-insights/trending/YycYngmyxX1_QMLpWOSm0g2 content esgSubNav
In This List

US FDA approves Novo Nordisk's drug for hemophilia B

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA approves Novo Nordisk's drug for hemophilia B

The U.S. FDA approved the biologics license application for Novo Nordisk A/S' REBINYN, a drug to treat adults and children with hemophilia B, a blood clotting disorder.

Novo Nordisk plans to launch the drug in the U.S. during the first half of 2018.